Successful Treatment of T‐cell Post‐Transplant Lymphoproliferative Disorder with the Retinoid Analog Bexarotene

T‐cell post‐transplant lymphoproliferative disorder (PTLD) is a rare life threatening complication of organ transplantation. It is usually resistant to treatment with reduction in immunosuppression or chemotherapy and carries a poor prognosis. We report on a combined kidney and pancreas transplant patient with Epstein–Barr virus (EBV) positive T‐cell PTLD that had recurred after chemotherapy and reduction in immunosuppression. The patient was successfully treated with bexarotene, a novel synthetic retinoid analog, achieving a complete clinical response. Bexarotene may be a promising treatment for T‐cell PTLD.